potassium voltage-gated channel subfamily A member 3Genealiases: HGK5 · HLK3 · HPCN3 · HUKIII · KV1.3 · MK3
Q-omics provides the consensus-scored KCNA3 profile across patient tissues and cancer cell-line models. KCNA3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KCNA3 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, KCNA3 RNA expression shows 18,857 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where KCNA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNA3 survival associations across molecular data types. KCNA3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNA3 RNA expression–survival associations across cancer types. High KCNA3 expression shows favorable associations in HNSC, SKCM, UCEC, LUAD, CESC and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KCNA3 RNA expression.
This table summarizes KCNA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KCNA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNA3 shows lower tumor expression in COAD, LUSC, UCEC, LUAD and THCA and higher tumor expression in KIRC. The COAD box plot shows higher KCNA3 RNA expression in normal versus tumor tissue (log2 FC = −1.538, t-test p < 0.001).
This table shows molecular features associated with KCNA3 in patient tissues and cancer cell lines. In patient samples, KCNA3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
